Elena Ridloff - 12 Mar 2021 Form 4/A - Amendment Insider Report for Kymera Therapeutics, Inc. (KYMR)

Role
Director
Signature
/s/ Bruce Jacobs, as Attorney-in-Fact
Issuer symbol
KYMR
Transactions as of
12 Mar 2021
Net transactions value
$0
Form type
4/A - Amendment
Filing time
15 Apr 2022, 16:15:21 UTC
Date Of Original Report
16 Mar 2021
Next filing
15 Apr 2022
SEC
View on sec.gov

Derivative Securities (e.g., puts, calls, warrants, options, convertible securities)

Type Sym Class Transaction Value $ Shares Change % * Price $ Shares After Date Underlying Class Amount Exercise Price Ownership Footnotes
transaction KYMR Stock Option (Right to Buy) Award $0 +20,919 $0.000000 20,919 12 Mar 2021 Common Stock 20,919 $56.10 Direct F1
* An asterisk sign (*) next to the price indicates that the price is likely invalid.

Explanation of Responses:

Id Content
F1 The shares subject to this option shall vest in thirty-six (36) equal monthly installments over three (3) years commencing on March 12, 2021.

Remarks:

This Amended Form 4 restates the original Form 4 in its entirety.